Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment-Reference-Cited by-同舟云学术

Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment

Published:2023-12-06 Issue:1 Volume:32 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Saito Yoshitaka,Uchiyama Kazuki,Takekuma Yoh,Komatsu Yoshito,Sugawara Mitsuru

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-023-08195-3.pdf

Reference26 articles.

1. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A et al (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 34:179–185

2. Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S (2018) Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology 94:191–199

3. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

4. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075

5. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translation, Cross-Cultural Adaptation, Reliability and Construct Validity of the FACT- EGFRI-18 Quality of Life Instrument from English into Portuguese;Revista Brasileira de Cancerologia;2024-07-04

2. Arzneimittelexantheme unter Immun- und zielgerichteter onkologischer Therapie;Die Dermatologie;2024-05-21

3. Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal Cancer;In Vivo;2024

4. Aspirin use and changes in circulating tumor DNA levels in patients with metastatic colorectal cancer;PAK J PHARM SCI;2024